76 related articles for article (PubMed ID: 3209828)
21. Determination of growth fraction index in mammary carcinoma using MIB-1 monoclonal antibody: estimation of whole tumor proliferative potential using biopsy specimens.
Oda K; Yokoi S; Kanda H; Shibuya M; Kamiya S; Horisawa M; Niinomi N; Suzuki M; Hayakawa S; Kishikawa S
Tokai J Exp Clin Med; 1995 Jul; 20(2):81-8. PubMed ID: 8797264
[TBL] [Abstract][Full Text] [Related]
22. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?
Trihia H; Murray S; Price K; Gelber RD; Golouh R; Goldhirsch A; Coates AS; Collins J; Castiglione-Gertsch M; Gusterson BA;
Cancer; 2003 Mar; 97(5):1321-31. PubMed ID: 12599241
[TBL] [Abstract][Full Text] [Related]
23. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.
Clark GM; Allred DC; Hilsenbeck SG; Chamness GC; Osborne CK; Jones D; Lee WH
Cancer Res; 1997 Dec; 57(24):5505-8. PubMed ID: 9407959
[TBL] [Abstract][Full Text] [Related]
24. Reactivity of a monoclonal antibody with tissues and tumors from the human breast. Immunohistochemical localization of a new antigen and clinicopathologic correlations.
Mariani-Costantini R; Barbanti P; Colnaghi MI; Ménard S; Clemente C; Rilke F
Am J Pathol; 1984 Apr; 115(1):47-56. PubMed ID: 6711680
[TBL] [Abstract][Full Text] [Related]
25. A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1.
Kreipe H; Heidebrecht HJ; Hansen S; Röhlk W; Kubbies M; Wacker HH; Tiemann M; Radzun HJ; Parwaresch R
Am J Pathol; 1993 Jan; 142(1):3-9. PubMed ID: 8093827
[TBL] [Abstract][Full Text] [Related]
26. [Ki-67 antigen, a cell cycle and tumor growth marker].
Seigneurin D; Guillaud P
Pathol Biol (Paris); 1991 Dec; 39(10):1020-8. PubMed ID: 1666669
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of double staining of MIB-1 and AgNORs in primary breast carcinoma.
Kidogawa H; Nanashima A; Yano H; Matsumoto M; Yasutake T; Nagayasu T
Anticancer Res; 2005; 25(6B):3957-62. PubMed ID: 16309183
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms.
Goldblum JR; Shannon R; Kaldjian EP; Thiny M; Davenport R; Thompson N; Lloyd RV
Mod Pathol; 1993 Nov; 6(6):663-8. PubMed ID: 7508113
[TBL] [Abstract][Full Text] [Related]
29. Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen.
Yu CC; Dublin EA; Camplejohn RS; Levison DA
Anal Cell Pathol; 1995 Jul; 9(1):45-52. PubMed ID: 7577754
[TBL] [Abstract][Full Text] [Related]
30. A technique for automatic/interactive assessment of the proliferating fraction of neoplastic cells in solid tumors. A methodological study on the Ki-67 immunoreactive cells in human mammary carcinomas, including a comparison with the results of conventional S-phase fraction assessments by means of DNA cytometry.
Parrado C; Falkmer UG; Höög A; Falkmer S; Ahrens O; Rius F; Grimelius L
Gen Diagn Pathol; 1996 Mar; 141(3-4):215-27. PubMed ID: 8705786
[TBL] [Abstract][Full Text] [Related]
31. Decreased nm23 expression, but not Ki-67 labeling index, is significantly correlated with lymph node metastasis of breast invasive ductal carcinoma.
Terasaki-Fukuzawa Y; Kijima H; Suto A; Takeshita T; Iezumi K; Sato S; Yoshida H; Sato T; Shimbori M; Shiina Y
Int J Mol Med; 2002 Jan; 9(1):25-9. PubMed ID: 11744991
[TBL] [Abstract][Full Text] [Related]
32. A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers.
Gee JM; Douglas-Jones A; Hepburn P; Sharma AK; McClelland RA; Ellis IO; Nicholson RI
J Pathol; 1995 Nov; 177(3):285-93. PubMed ID: 8551391
[TBL] [Abstract][Full Text] [Related]
33. Clinical relevance of the distribution of the lesions in 500 consecutive breast cancer cases documented in large-format histologic sections.
Tot T
Cancer; 2007 Dec; 110(11):2551-60. PubMed ID: 17932896
[TBL] [Abstract][Full Text] [Related]
34. Proliferation of invasive breast carcinomas and colorectal adenocarcinomas: an immunohistochemical in situ investigation with the monoclonal antibody Ki-67.
Horny HP; Horst HA
Zentralbl Allg Pathol; 1988; 134(6):547-54. PubMed ID: 3213288
[TBL] [Abstract][Full Text] [Related]
35. Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma.
Gasparini G; Dal Fior S; Pozza F; Bevilacqua P
Breast Cancer Res Treat; 1989 Dec; 14(3):329-36. PubMed ID: 2482095
[TBL] [Abstract][Full Text] [Related]
36. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome.
Lee AK; Loda M; Mackarem G; Bosari S; DeLellis RA; Heatley GJ; Hughes K
Cancer; 1997 Feb; 79(4):761-71. PubMed ID: 9024714
[TBL] [Abstract][Full Text] [Related]
37. [Tumor properties of primary tumors and local recurrence of breast cancer].
Torsten U; Opri F; Moreno-Richter I; Weitzel HK
Zentralbl Gynakol; 1993; 115(3):99-104. PubMed ID: 8385409
[TBL] [Abstract][Full Text] [Related]
38. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
39. Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. An immunohistochemical study.
Wrba F; Chott A; Reiner A; Reiner G; Markis-Ritzinger E; Holzner JH
Oncology; 1989; 46(4):255-9. PubMed ID: 2662089
[TBL] [Abstract][Full Text] [Related]
40. [Assessment of the prognosis of breast cancer. Determination of the growth fraction using monoclonal antibody Ki-67].
Lellé RJ
Fortschr Med; 1989 Jun; 107(17):380-1. PubMed ID: 2663680
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
